Local Antioxidant Therapy Vasoconstriction Effects in Different Races

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

October 15, 2018

Primary Completion Date

May 15, 2024

Study Completion Date

June 8, 2024

Conditions
Cardiovascular DiseasesCardiovascular Risk FactorVasoconstriction
Interventions
DRUG

Control (Norepinephrine)

This intervention is aimed at assessing the vascular responsiveness to norepinephrine, an alpha 1-agonist, in white and black men and women across a series of ascending dose concentrations.

DRUG

Norepinephrine + Ascorbic Acid

This intervention is meant to globally assess the impact of oxidative stress on vasoconstrictor responses by scavenging numerous oxidative molecules.

DRUG

Norepinephrine + L-NAME

This intervention is meant to assess the impact of endothelium-derived nitric oxide on vasoconstrictor responses by inhibiting production of this source of nitric oxide.

DRUG

Norepinephrine + L-NAME + Ascorbic Acid

This intervention is meant to assess the combined impact of scavenging oxidative stress and inhibiting endothelium-derived nitric oxide on vasoconstrictor responses.

Trial Locations (1)

76019

Science and Engineering Research and Innovation Building, Arlington

All Listed Sponsors
lead

The University of Texas at Arlington

OTHER

NCT03684213 - Local Antioxidant Therapy Vasoconstriction Effects in Different Races | Biotech Hunter | Biotech Hunter